Clinical trial · no report yet · Phase 1
TAR-210
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
- NCT05567185 ↗
- Active, not recruiting
- Janssen Pharmaceutical K.K.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| Bluesky threads | 4 | |
| X threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 Study to Evaluate the Tolerability, Safety, and Pharmacokinetics of TAR-210 in Japanese Participants With Bladder Cancer and Selected FGFR Mutations or Fusions
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Urinary Bladder Neoplasms; Receptors, Fibroblast Growth Factor
- Interventions
- Erdafitinib Intravesical Delivery System
- Arms
- Dose Escalation: Erdafinitib Intravesical Delivery System · Experimental
- Enrollment
- 5
- Primary outcomes
- Number of Participants with Dose-limiting Toxicity (DLT)
- Sponsor
- Janssen Pharmaceutical K.K.
- Start
- Mar 3, 2023
- Primary completion
- Mar 11, 2025
- Results posted
- No
- Registry record
- NCT05567185 · updated Aug 28, 2026